Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of sorafenib tosylate in treating
patients with liver cancer who have undergone a liver transplant. Sorafenib tosylate may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor. Giving sorafenib after liver transplant may be an effective
treatment for liver cancer